A novel molecule that prevents T-cells from orchestrating asthma brought on by allergens has been discovered by Sanford-Burnham Medical Research Institute (Sanford-Burnham) researchers. The findings, published on May 12 in Proceedings of the National Academy of Sciences (PNAS), show promise for a new potent therapeutic agent to treat asthma, a chronic disease affecting more than 25 million Americans.
"We have identified a synthetic molecule, a sulfate monosaccharide, that inhibits the signal that recruits T-cells to the lungs to start an asthma attack," said Minoru Fukuda, Ph.D., adjunct professor in the Tumor Microenvironment and Metastasis Program at Sanford-Burnham. "The molecule substantially lessened asthma symptoms such as inflammation, mucus production, and airway constriction."
The study, performed in mouse models for asthma research, showed that the synthetic sulfate monosaccharide blocks the interaction between chemokine CCL20a T-cell signaling proteinand heparin sulfate, a molecule that protects and immobilizes CCL20 on epithelial cells in the lung. Blocking this interaction stalled the recruitment of the T-cells that trigger inflammation. The favorable results were achieved when the novel molecule was administered intravenously as well as by inhalation.
"There is currently no cure for asthma, and asthma control remains elusive for many patients, so there is still a need for research to find new therapies," says Mike Tringale, senior vice president at the Asthma and Allergy Foundation of America (AAFA), a national asthma patient organization that has declared May National Asthma Awareness Month.
"Pulmonary inhalation of this new molecule may help reduce asthma symptoms by suppressing chemokine-mediated inflammatory responses," said Fukuda. "We look forward to the further development of the molecule to treat the millions of people who suffer from this chronic disease."
Asthma is a chronic (long-term) lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing (a whistling sound when you breathe), chest tightness, shortness of breath, and coughing. The effects are usually temporary, but if the episode is severe, a person may need emergency treatment to restore normal breathing.
Asthma affects people of all ages, but it most often starts during childhood. In the United States, more than 25 million people are known to have asthma, and 60 percent of cases are allergic asthma. About 5 million of these people are children. Despite the availability of treatments, asthma remains poorly controlled among many patients. People with asthma can be of any race, age, or sex, and treatment costs billions of dollars each year.